Autologous Bone Marrow Transplanted Via Transendocardial Catheter to Chronic Myocardial Infarct Border Zone (TABMMI)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00507468 |
Recruitment Status :
Completed
First Posted : July 26, 2007
Last Update Posted : November 3, 2009
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
The object of this open-labeled, uncontrolled pilot study was to investigate the safety and feasibility of percutaneously transplanting autologous bone marrow (ABM) cells into the myocardium using the helical needle transendocardial (TE) delivery system in stable coronary patients with ventricular dysfunction due to chronic myocardial infarction (MI).
A secondary goal was to assess the possibility that such cell injections could improve ejection fraction (EF).
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Ventricular Dysfunction Myocardial Infarction | Procedure: Transendocaridal Transplantation of Autologous Bone Marrow | Phase 1 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 20 participants |
Allocation: | Non-Randomized |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Official Title: | Autologous Bone Marrow Transplanted Via Transendocardial Catheter to Chronic Myocardial Infarct Border Zone |
Study Start Date : | December 2005 |
Actual Primary Completion Date : | March 2009 |
Actual Study Completion Date : | August 2009 |

- Procedure: Transendocaridal Transplantation of Autologous Bone Marrow
Single treatment, harvest and transplant of patients own bone marrow. Cells are delivered to the myocardium via transendocardial delivery catheter.
- Safety of treatment [ Time Frame: 6 months ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Must be 18 years of age or older
- Able to give informed consent
- Must have documentation of prior myocardial infarction with left ventricular ejection fraction of less than 40 percent at baseline
- Must be a candidate for percutaneous heart catheterization
- Must have identifiable area of transmural scar within the left ventricle
Exclusion Criteria:
- Be a candidate for concurrent ventricular surgical restoration, AICD placement or valvular surgery
- Clinical evidence of infection
- Other complicating cardiovascular abnormalities
- Clinically significant electrocardiographic abnormalities
- Active malignancy
- Recent history or drug or alcohol abuse
- Pregnancy, planned or current
- Artificial aortic valve
- Ejection fraction less than 30 percent at baseline
- Myocardial infarction in the past 4 weeks

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00507468
Argentina | |
Swiss Clinic | |
Buenos Aires, Argentina, 1118 | |
Argentine Institute of Diagnosis and Treatment | |
Buenos Aires, Argentina, 1122 |
Principal Investigator: | Luis de la Fuente, MD | Argentine Institute of Diagnosis and Treatment |
Responsible Party: | Peter Altman, BioCardia, Inc |
ClinicalTrials.gov Identifier: | NCT00507468 |
Other Study ID Numbers: |
ABM-MI-10 |
First Posted: | July 26, 2007 Key Record Dates |
Last Update Posted: | November 3, 2009 |
Last Verified: | November 2009 |
bone marrow autologous ejection fraction left ventricle |
heart attack myocardial infarction left ventricular dysfunction post myocardial infarction |
Myocardial Infarction Ventricular Dysfunction Infarction Ischemia Pathologic Processes |
Necrosis Myocardial Ischemia Heart Diseases Cardiovascular Diseases Vascular Diseases |